0.01
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aton
Its shares trade on Euronext Paris under the ticker ALTAO.PA. It has been listed since 17 December 2007. In the fiscal year to 31 December 2024, it reported revenue of €614,000 and a net loss of €1.1m. At that date it held total assets of €6.5m and shareholders' equity of €791,000.
Hybrigenics SA operates as a biopharmaceutical company which engages in the research and development of targets and therapies for the treatment of proliferative diseases. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2007-12-17. The company specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The firm is specialized in the research and development (R&D) of drugs to fight cancer. The company is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. The company operates through Hybrigenics Corporation and Imaxio.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Dec 2007
- Employees
- 17
- Website
- hybrigenics.com ↗
Leadership
Pay as last reported
- Ms. Ayikoele AtayiChairman of the Board, Chief Executive Officer, since 2022€47,500
- Dr. Pierre EftekhariDirector
- Mr. Enrico BastianelliIndependent Director€200,000
- Mr. Hadrien LanvinIndependent Director
- Ms. Virginie MiathIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hybrigenics SA possesses robust research and development capabilities, allowing them to innovate and develop cutting-edge biotechnology products and solutions.
- The company holds a substantial intellectual property portfolio, which provides them with a competitive advantage and facilitates protection of their innovative technologies and discoveries.
- Hybrigenics SA has built a strong brand reputation in the biotechnology industry through their quality products, reliable services, and successful collaborations.
- With a global presence, Hybrigenics SA has access to diverse markets worldwide, enabling them to tap into various opportunities and reach a wide customer base.
Weaknesses
- The company's revenue is highly dependent on a few key customers, which poses a risk if any of these customers reduce their purchases or choose to work with competitors.
- Hybrigenics SA has a relatively limited range of products and services, which may restrict their ability to cater to diverse customer demands and limit revenue generation.
Opportunities
- The increasing global demand for biotechnology products presents a significant opportunity for Hybrigenics SA to expand their market presence and capitalize on the growing industry.
- Forming strategic partnerships and collaborations with other leading companies or research institutions can enhance Hybrigenics SA's research capabilities, diversify their product offering, and increase market penetration.
Threats
- The biotechnology industry is highly competitive, with numerous established players and emerging startups. Hybrigenics SA faces the risk of losing market share to competitors who may offer similar or more innovative solutions.
- Adhering to complex regulatory frameworks, obtaining necessary approvals, and ensuring compliance with evolving industry regulations pose challenges and may impact Hybrigenics SA's operations and product development timeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.